Ginkgo Bioworks
Runs an automated cell-engineering foundry, selling R&D services, lab automation, and biological data to industry.
Something off on this page? Send us feedback.
Profile
Runs an automated foundry that engineers living cells under contract across many industries, selling the R&D service itself alongside the automation hardware and data tools built around it. Revenue depends on long, customer-specific programs rather than one flagship product, with a biosecurity monitoring unit being spun out to sharpen the focus.
Engineers living cells to order rather than developing its own drugs, treating biology as a manufacturing platform. Founded in 2008 by MIT synthetic-biology researchers, it runs an automated foundry performing strain engineering and cell-line optimization under multi-year contracts, delivering a working organism and the process to run it.
The platform sells lab-automation hardware built around its own automation cart and a data-generation service that returns model-ready assay results to pharmaceutical and industrial customers. These tools are increasingly packaged as a productized autonomous lab, run in-house or accessed as a managed cloud service.
A pathogen-monitoring and biothreat-intelligence unit built during the pandemic is being spun out as an independent company, narrowing the platform to core cell engineering. Roughly half the workforce was cut after the 2021 stock-market debut, and a reverse stock split kept the exchange listing compliant.
Company facts
Categories
Key statistics
Year to date −19.9% · Average volume (30d) 1.1M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| Aug 18, 2026 | Guggenheim | Initiate | Buy | |
| Aug 7, 2026 | Cowen & Co. | Downgrade | Buy | Hold |
| Aug 7, 2026 | TD Cowen | Downgrade | Buy | Hold |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | −$0.90 | −$0.75 | +16.2% | $24.1M | $20.2M | −16.2% | −9.28% |
| May 7, 2026Q1 FY26 | −$1.21 | −$1.28 | −5.7% | $42.9M | $19.5M | −54.6% | −13.47% |
| Feb 26, 2026Q4 FY25 | −$1.80 | −$1.42 | +21.1% | $37.1M | $33.0M | −11.0% | −30.48% |
| Nov 6, 2025Q3 FY25 | −$1.24 | −$1.45 | −16.9% | $37.6M | $38.8M | +3.4% | −20.80% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $48.3M | $49.6M | $38.8M | $33.4M | $19.5M | $20.2M | |
| Gross profit | $36.3M | $34.8M | $26.0M | $41.5M | $3.6M | $18.4M | |
| Operating income | −$89.0M | −$65.5M | −$90.0M | −$70.8M | −$71.4M | −$58.5M | |
| Net income | −$91.0M | −$60.3M | −$80.8M | −$80.8M | −$82.6M | −$46.7M | |
| Diluted EPS | −$1.68 | −$1.10 | −$1.45 | −$1.43 | −$1.39 | −$0.75 | |
| Gross margin | 75.1% | 70.1% | 67.0% | 124.4% | 18.4% | 91.5% | |
| Operating margin | -184.1% | -132.1% | -231.8% | -211.9% | -366.5% | -290.5% |
Fiscal years (4-quarter sums)FY21 $313.8M · FY22 $477.7M · FY23 $251.5M · FY24 $227.0M · FY25 $170.2M
Revenue by product · Q4 FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $302.2M · Total debt $404.1M · Total assets $990.0M · Shareholders' equity $420.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 65.32M · Float 47.85M · 73.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 4.28M | 6.56% | 13F | Aug 7, 2026 |
| Cascade Investment, L.L.C. | 3.62M | 7.50% | 13G | Nov 14, 2025 |
| Viking Global Investors LP | 3.58M | 5.48% | 13F | Aug 14, 2026 |
| Erste Asset Management GmbH | 2.54M | 3.88% | 13F | Jul 28, 2026 |
| Baillie Gifford & Co | 2.39M | 3.66% | 13F | Aug 6, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 24, 2026 | Steven P. Coen | officer: See remarks | −330 | $6.98 |
| Jul 17, 2026 | Steven P. Coen | officer: See remarks | −752 | $7.90 |
| May 22, 2026 | Steven P. Coen | officer: See remarks | −307 | $8.33 |
| Apr 17, 2026 | Steven P. Coen | officer: See remarks | −324 | $7.95 |
| Apr 13, 2026 | Steven P. Coen | officer: See remarks | −33,171 | $6.41 |
Peers
- Charles River Laboratories
Largest global CRO for ADME/DMPK, antibody discovery, and biologics testing
- Recursion Pharmaceuticals
Automated lab-generated biological data feeding AI drug-discovery models
- AbCellera Biologics
AI/wet-lab antibody discovery platform with milestone-and-royalty partner deals
- Absci
Generative AI antibody design and developability services for pharma partners
- Codexis
AI-driven enzyme-engineering platform overlapping pharma biocatalyst R&D
- Schrödinger
In silico molecular design vs wet-lab automation for pharma discovery budgets
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Ginkgo Bioworks | $7.03 | +0.86% | $454.7M | — | — | 4.1 | −59.4% |
| Charles River Laboratories | $291.50 | +0.04% | $14.04B | — | 23.7 | 3.5 | −2.7% |
| Recursion Pharmaceuticals | $3.35 | +0.60% | $1.75B | — | — | 31.9 | −61.8% |
| AbCellera Biologics | $11.37 | +0.24% | $3.47B | — | — | 52.4 | −76.3% |
| Absci | $8.75 | +0.34% | $1.48B | — | — | 945.2 | −49.4% |
| Codexis | $1.61 | +1.90% | $171.0M | — | — | 2.2 | −2.7% |
| Schrödinger | $19.67 | −0.15% | $1.47B | — | — | 5.7 | +7.5% |
| Median | — | 23.7 | 18.8 | −26.1% |